Clinical Trial: Maternal Plasmatic Regulatory T Cells and Th17 as Possible Diagnosis Markers of Acute Chorioamnionitis
Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Contribution of the Study of Maternal Plasmatic Regulator T Cells and Th17 for the Diagnosis of Acute Chorioanmionitis Among Women Hospitalized for Premature Rupture of Fetal Membranes (PPROM) Between
Brief Summary: The purpose of this study is to evaluate if regulator T cells (Treg) and Th17 level modifications in maternal blood and placenta could be correlated to a chorioamnionitis, in women hospitalized for PPROM.
Detailed Summary:
Acute chorioamnionitis is the principal antecedent of premature birth and an important contributor to specific neonatal and other complications that may extend throughout subsequent life. The PPROM is a high risk condition for developing chorioamnionitis. Available biological markers have a low prognostic value. Indeed, currently the diagnosis of intra-uterine infection relies only on placental cultures and anatomo-pathological exam after the delivery.
Moreover, pregnancy is an immunologic particular condition. Indeed an immune tolerance is required with respect to the fetus and is mediated by Treg lymphocytes, which suppressed Th17 activity.
Recent studies have shown among women with frequent miscarriages, a balance between Treg and Th17, with a decrease in Treg number and an increase in Th17 number in decidua and blood.
In case of infection, the immune pro-inflammatory response (Th17) is restored in peripheric tissues and in blood in order to limit the extention of intra-uterine infection. This restoration of this pro-inflammatory response could be due to a modification of Treg number ou tolerogenic activity.
In this context, our hypothesis is that chorioamnionitis will lead to a decrease of treg proportion and an increase of Th17 proportion in lymphocyte populations of maternal blood and placenta, with a back to values near than which is observed in beginning of pregnancy or in no pregnant women.
Sponsor: Centre Hospitalier Universitaire Dijon
Current Primary Outcome: Evaluate the percentage of Treg in maternal blood at the time of admission [ Time Frame: the day of delivery or 7 days after the admission if no delivery ]
Original Primary Outcome: Evaluate the percentage of Treg in maternal blood at the time of admission [ Time Frame: until the delivery or 7 days if no delivery ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Centre Hospitalier Universitaire Dijon
Dates:
Date Received: May 31, 2012
Date Started: March 2013
Date Completion: September 2016
Last Updated: December 3, 2014
Last Verified: April 2013
